← Human Trials & Peer-Reviewed Studies
25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis.
Plain-language guide to PMID 22798536 (2012): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 22798536
- Journal
- Clinical journal of the American Society of Nephrology : CJASN
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Armas LA et al. (5 authors)
- DOI
- 10.2215/CJN.12761211
- Registered trial
- NCT00511225
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.
Recent understanding of extrarenal production of calcitriol has led to the exploration of native vitamin D treatment in dialysis patients.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
This randomized, double-blind, placebo-controlled trial of 15 weeks of oral cholecalciferol in subjects with stage 5 CKD requiring maintenance hemodialysis was conducted from November of 2007 to March of 2010.
The time course of serum 25-hydroxyvitamin D was measured over the course of treatment.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
Additionally, blood was drawn at baseline and last visit for calcium, phosphorus, calcitriol, and parathyroid hormone levels.
What Was Measured
Topics PubMed links to this paper include Biomarkers, Calcium, Chi-Square Distribution, Cholecalciferol, Dietary Supplements, Kidney Failure, Chronic and Linear Models.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (Clinical journal of the American Society of Nephrology : CJASN), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.